Scientists at City of Hope identified a protein that could help prevent CAR T-cell therapy antigen escape. The research, published in the journal Cell, could lead to more personalized therapies that improve cancer patients’ survival.
Researchers from City of Hope have developed a “plug-and-play” technology that adds engineered molecules to chimeric antigen receptor T cells after treatment, allowing scientists to better control the cells and redirect them to attack different types of cancer. The preclinical study offers a more flexible way to help CAR T cells keep pace with mutating tumors.
